A cytochemical assay for osteoclast cathepsin K activity

Cell Biochemistry and Function

Volumn 21, Issue 3, 2003, Pages 231-234

  Dodds, Robert A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cathepsin K; Osteoclasts; Quantitative cytochemistry

Indexed keywords

CATHEPSIN K; CYSTEINE PROTEINASE;

ANIMAL CELL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOCHEMISTRY; ENZYME ACTIVITY; ENZYME LOCALIZATION; FROZEN SECTION; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; QUANTITATIVE CYTOCHEMICAL ASSAY;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CATHEPSINS; DIPEPTIDES; FLUORESCENT DYES; HISTOCYTOCHEMISTRY; HUMANS; OSTEOCLASTS; RATS; SENSITIVITY AND SPECIFICITY; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 0042734863     PISSN: 02636484     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbf.1078     Document Type: Conference Paper

References (38)

1. Yamashita DS, Dodds RA. Cathepsin K and the design of inhibitors of cathepsin K. Curr Pharm Des 2000; 6: 1-24.
2. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989; 245: 855-857.
3. Baron R, Neff L, Brown W, Courtoy PJ, Louvard D, Farquhar MG. Polarized secretion of lysosomal enzymes: co-distribution of cation-independent mannose-6-phosphate receptors and lysosomal enzymes along the osteoclast exocytic pathway. J Cell Biol 1988; 106: 1863-1872.
4. Vaananen HK, Karhukorpi EK, Sundquist K, et al. Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J Cell Biol 1990; 111: 1305-1311.
5. Hall TJ, Chambers TJ. Molecular aspects of osteoclast function. Inflamm Res 1996; 45: 1-9.
6. Hill PA, Buttle DJ, Jones SJ, et al. Inhibition of bone resorption by selective inactivators of cysteine proteinases. J Cell Biochem 1994; 56: 118-130.
7. Debari K, Sasaki T, Udagawa N, Rifkin BR. An ultrastructural evaluation of the effects of cysteine-proteinase inhibitors on osteoclastic resorptive functions. Calcif Tiss Int 1995; 56: 566-570.
8. Delaisse JM, Eeckhout Y, Vaes G. In vitro and in vivo evidence for the involvement of cysteine proteinases in bone resorption. Biochem Biophys Res Commun 1984; 125: 441-447.
9. Lerner UH, Grubb A. Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy. J Bone Min Res 1992; 7: 433-439.
10. Delaisse JM, Boyde A, Maconnachie E, et al. The effects of inhibitors of cysteine proteinases and collagenase on the resorptive activity of isolated osteoclasts. Bone 1987; 8: 305-313.
11. Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996; 271: 12511-12516.
12. Tezuka K-i, Tezuka Y, Maejima A, et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 1994; 269: 1106-1109.
13. Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett 1995; 357: 129-134.
14. Brömme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe-Seyler 1995; 376: 379-384.
15. Li YP, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko P. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res 1995; 10: 1197-2202.
16. Inaoka T, Bilbe G, Ishibashi O, Tezuka K-i, Kamegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun 1995; 206: 89-96.
17. Fukunishi S, Iwata Y, Mort JS. Immunolocalization of cathepsin K at sites of bone resorption. J Orthop Res 1997; 22: 586.
18. Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K: expression, purification, activation, and substrate identification. J Biol Chem 1996; 271: 12517-12524.
19. Brömme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 1996; 271: 2126-2132.
20. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998; 273: 32347-32352.
21. Greenspan A. Sclerosing bone dysplasias - a target-site approach. Skeletal Radiol 1991; 20: 561-583.
22. Samsethsiri P, Hitt OK, Eyring EJ, Frost HM. Tetracycline-based study of bone dynamics in pycnodysostosis. Clin Orthoped Rel Res 1971; 74: 301-312.
23. Cabrejas ML, Fromm GA, Roca JF, et al. Pycnodysostosis: some aspects concerning kinetics of calcium metabolism and bone pathology. Amer J Med Sci 1976; 271: 215-220.
24. Meredith SC, Simon MA, Laros GS, Jackson MA. Pycnodysostosis. A clinical, pathological, and ultramicroscopic study of a case. J Bone Joint Surg 1978; 60: 1122-1127.
25. Elmore SM, Nance WE, McGee BJ, Montmollin ME, Engel E. Pycnodysostosis, with a familial chromosome anomaly. Amer J Med 1996; 40: 273-282.
26. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273: 1236-1238.
27. Johnson MR, Polymeropoulos MH, Vos HL, Ortiz de Luna RI, Francomano CA. A nonsense mutation in the cathepsin K gene observed in a family with pyconodysostosis. Genome Res 1996; 11: 1050-1055.
28. Saftig P, Hunziger E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA 1998; 95: 13453-13458.
29. Gowen M, Lazner F, Dodds RA, et al. Cathepsin K knockout mice develop osteoporosis due to a deficit in matrix degradation but not mineralization. J Bone Miner Res 1999; 14: 1654-1663.
30. Votta BJ, Levy MA, Badger A, et al. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J Bone Miner Res 1997; 12: 1396-1406.
31. Thompson SK, Halbert SM, Bossard MJ, et al. Design of potent and selective human cathepsin K inhibitors which span the active site. Proc Natl Acad Sci USA 1997; 94: 14249-14254.
32. Aibe K, Yazawa H, Abe K, et al. Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. Biol Pharm Bull 1996; 19: 1026-1031.
33. Van Noorden CJ, Vogels IM, Smith RE. Localization and cytophotometric analysis of cathepsin B activity in unfixed and undecalcified cryostat sections of whole rat knee joints. J Histochem Cytochem 1989; 37: 617-624.
34. Chayen J, Bitensky L (eds). Practical Histochemistry (2nd edn). John Wiley & Sons, Ltd: Chichester.
35. Dodds RA, Gowen M, Bradbeer JN. Microcytophotometric analysis of human osteoclast metabolism: the lack of activity in certain oxidative pathways indicates an inability to sustain biosynthesis during resorption. J Histochem Cytochem 1994; 42: 599-560.
36. Dodds RA, James IE, Rieman D, et al. Osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J Bone Miner Res 1998; 16: 478-486.
37. Lark MW, Stroup GB, James IE, et al. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. Bone 2002; 30: 746-753.
38. James IE, Marquis RW, Blake SM, et al. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro. J Biol Chem 2001; 276: 11507-11511.